Skip to main content
HUAPONT LIFE SCIENCES CO., LTD. logo

HUAPONT LIFE SCIENCES CO., LTD. — Investor Relations & Filings

Ticker · 002004 ISIN · CNE000001JJ6 LEI · 3003009TGXJC0JJVTJ07 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,461 across all filing types
Latest filing 2025-03-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002004

About HUAPONT LIFE SCIENCES CO., LTD.

https://www.huapont.com.cn

HUAPONT LIFE SCIENCES CO., LTD. operates as a diversified entity specializing in the research, development, manufacturing, and distribution of pharmaceutical and chemical solutions. The company holds a prominent position in the dermatology sector, providing a comprehensive range of therapeutic products for various skin disorders. Its pharmaceutical operations extend to the production of high-quality active pharmaceutical ingredients (APIs) and finished dosage forms. Beyond human health, the organization maintains a significant footprint in the agrochemical sector, focusing on the development and supply of crop protection products, including herbicides and pesticides. The company also integrates healthcare services into its business model, overseeing the operation of medical facilities and specialized clinics. Its strategic focus centers on technological advancement and the maintenance of a robust supply chain to support its global commercial activities.

Recent filings

Filing Released Lang Actions
关于实际控制人部分股份解除质押的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the release of a portion of pledged shares by the actual controller of the company, including detailed information about the shareholder, the number of shares released from pledge, and cumulative pledge status. It does not contain financial statements, earnings data, or management discussion. It is a specific disclosure about share pledge status, which fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about share pledge changes and not a financial report or capital raising event.
2025-03-28 Chinese
关于全资子公司获得《药品注册证书》的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Huabang Life Health Co., Ltd. regarding its wholly-owned subsidiary receiving a drug registration certificate from the National Medical Products Administration. It details the drug's basic information, approval, and potential impact on the company. The document is short (976 characters) and serves as a formal announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management analysis. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a Regulatory Filing (RNS) as it is a regulatory announcement about a product approval and its business impact without fitting other specific categories.
2025-03-27 Chinese
关于实际控制人部分股份质押的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the pledge of shares by the company's actual controller and related parties. It details the number of shares pledged, the proportion of shares, pledge terms, and assurances about the impact on the company. There is no financial statement, earnings data, or report attached or referenced. The document is a regulatory announcement about share pledging activity by major shareholders, which fits the category of a Regulatory Filing (RNS) as it does not fall under more specific categories like capital changes or director dealings. The document length is short and it is a standalone announcement without financial data or report content.
2025-03-24 Chinese
关于收到《关于华邦生命健康股份有限公司非公开发行科技创新可交换公司债券符合深交所挂牌条件的无异议函》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Huabang Life Health Co., Ltd. regarding the receipt of a 'No Objection Letter' from the Shenzhen Stock Exchange for the company's non-public issuance of technology innovation exchangeable corporate bonds. The text includes details about board and shareholder meetings approving the bond issuance, adjustments to the issuance scale, and regulatory compliance statements. The document is short (1149 characters) and primarily serves as an official notification about regulatory approval and next steps, rather than containing detailed financial data or the bond issuance itself. It does not contain financial statements or detailed analysis, nor is it a transcript or presentation. Therefore, it fits best as a Regulatory Filing (RNS) since it is a regulatory announcement about compliance and approvals related to financing activities but not the financing update itself or a full report.
2025-03-21 Chinese
关于使用暂时闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Huabang Life Health Co., Ltd. regarding the use of temporarily idle own funds for cash management through low-risk, short-term financial products. It details the investment purpose, amount, risk control measures, and board approval. The document is an announcement of a financing or capital management activity, specifically about the company's cash management and investment of idle funds. It is not a full financial report, audit, or earnings release, nor is it a regulatory filing or meeting material. The content fits best under Capital/Financing Update (CAP) as it relates to updates on company financing activities and capital usage.
2025-03-06 Chinese
第八届董事会第二十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 22nd meeting of the 8th Board of Directors of Huabang Life Health Co., Ltd. It includes details about the meeting's convening, voting results, and approved proposals such as the use of idle funds for cash management and the 2025 financial budget report. There is no detailed financial data or comprehensive report content, only the announcement of board decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management. The document length is short and it does not contain full financial statements or detailed analysis, so it is not an Annual Report or Interim Report. Therefore, the correct classification is MANG with high confidence.
2025-03-06 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.